Syneos Health, Inc. (NASDAQ:SYNH – Get Rating) – Equities research analysts at Jefferies Financial Group lowered their FY2022 earnings per share (EPS) estimates for Syneos Health in a research note issued to investors on Monday, April 25th. Jefferies Financial Group analyst D. Windley now expects that the company will post earnings of $4.41 per share for the year, down from their previous forecast of $4.65. Jefferies Financial Group currently has a “Hold” rating and a $75.00 price target on the stock. Jefferies Financial Group also issued estimates for Syneos Health’s Q4 2022 earnings at $1.40 EPS.
A number of other research firms also recently weighed in on SYNH. StockNews.com began coverage on shares of Syneos Health in a research note on Thursday, March 31st. They set a “hold” rating on the stock. Mizuho cut their price target on shares of Syneos Health from $109.00 to $94.00 and set a “buy” rating on the stock in a research note on Monday, March 7th. Deutsche Bank Aktiengesellschaft began coverage on shares of Syneos Health in a research note on Monday, April 11th. They set a “buy” rating and a $102.00 price target on the stock. Barclays cut their price target on shares of Syneos Health from $115.00 to $105.00 and set an “overweight” rating on the stock in a research note on Thursday, January 27th. Finally, Zacks Investment Research raised shares of Syneos Health from a “sell” rating to a “hold” rating and set a $95.00 price target on the stock in a research note on Monday, January 17th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $100.33.
Syneos Health (NASDAQ:SYNH – Get Rating) last announced its earnings results on Thursday, February 17th. The company reported $1.36 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.34 by $0.02. Syneos Health had a net margin of 4.50% and a return on equity of 12.69%. The firm had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.40 billion. During the same quarter last year, the business earned $1.00 earnings per share. Syneos Health’s revenue was up 20.5% compared to the same quarter last year.
A number of institutional investors have recently added to or reduced their stakes in SYNH. Signaturefd LLC increased its stake in Syneos Health by 328.6% during the 4th quarter. Signaturefd LLC now owns 240 shares of the company’s stock worth $25,000 after buying an additional 184 shares during the period. Clearstead Advisors LLC acquired a new position in Syneos Health during the 3rd quarter worth $28,000. Independence Bank of Kentucky acquired a new position in Syneos Health during the 1st quarter worth $28,000. Daiwa Securities Group Inc. grew its holdings in Syneos Health by 71.0% during the 3rd quarter. Daiwa Securities Group Inc. now owns 354 shares of the company’s stock worth $31,000 after acquiring an additional 147 shares in the last quarter. Finally, AllSquare Wealth Management LLC acquired a new position in Syneos Health during the 3rd quarter worth $31,000. 94.63% of the stock is currently owned by hedge funds and other institutional investors.
In other news, CAO Donna Hildebrand Kralowetz sold 1,055 shares of the firm’s stock in a transaction on Monday, January 31st. The shares were sold at an average price of $90.00, for a total value of $94,950.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.29% of the company’s stock.
About Syneos Health (Get Rating)
Syneos Health, Inc provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development.
- Get a free copy of the StockNews.com research report on Syneos Health (SYNH)
- Las Vegas Sands Stock Could be a Winning Bet Down Here
- Newmont Corporation is the Same as It’s Always Been Which is Why It’s a Buy
- Simpson Manufacturing Co. Hits The Nail On The Head, Again
- The Sherwin-Williams Company Bottoms Above Institutional Support
- What To Make Of Activision Blizzard (NASDAQ: ATVI)
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.